CAL
OLMA icon

Capital Advisors Ltd’s Olema Pharmaceuticals OLMA Stock Holding History

Capital Advisors Ltd’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-31
Closed – – 1435
2022
Q2 		$0 Buy
+31
New +$98 ﹤0.01% 1224

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Capital Advisors Ltd's OLMA Position: Q3 2022 in Review

Capital Advisors Ltd sold out of Olema Pharmaceuticals (OLMA) in Q3 2022, closing a stake of 31 shares.

Capital Advisors Ltd first reported a position in OLMA in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 73 funds tracked by Wall St. Rank hold OLMA as of Q3 2022.

  • Capital Advisors Ltd reported no remaining Olema Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 31 Olema Pharmaceuticals shares in Q3 2022.
  • Capital Advisors Ltd first reported a position in Olema Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Capital Advisors Ltd's Olema Pharmaceuticals position peaked at $0 in Q2 2022.
  • 73 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2022.

Based on Capital Advisors Ltd's 13F filing for Q3 2022, filed 9 Nov 2022.